Stocks
Intra-Cellular Therapies (ITCI) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -254 090% | -1 026% | -349.6% | -105.8% | -34.4% | -25.7% | ||
| Changes by years, y/y, % | +253 064pp | +677pp | +244pp | +71pp | -89.2% | ||||
Intra-Cellular Therapies. EBITDA margin, %
Intra-Cellular Therapies. EBITDA margin, changes, pp
Intra-Cellular Therapies (ITCI) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA margin, % | ? | -51.1% | -42.8% | -23.5% | -25.8% | -14.4% | -25.7% | |
| Changes by years, y/y, % | +157pp | +117pp | +54pp | +28pp | +37pp | |||
| Changes by quarters, q/q, % | +3pp | +8pp | +19pp | -2pp | +11pp | |||
